Tag Archives: Relyvrio

ALS Drug Pulled From Market; It Should Never Have Gone to Market – And A New Methodology to Better Treat Neurodegeneration

Although a public corporation used poor study design and manipulated data in a small study (Phase II) that found no benefit of the drug, and that truncated needed efficacy studies (Phase III), Relyvrio was approved in 2022 by physicians at the FDA to treat ALS. Now that efficacy studies (Phase III) have been performed in …

Continue reading “ALS Drug Pulled From Market; It Should Never Have Gone to Market – And A New Methodology to Better Treat Neurodegeneration”